Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:activeIngredient |
peramivir
|
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J05AH02
|
| gptkbp:brand |
gptkb:Rapivab
peramivir Alpivab Peramiflu |
| gptkbp:CASNumber |
330600-85-6
|
| gptkbp:chemicalFormula |
C15H28N4O4
|
| gptkbp:developer |
gptkb:BioCryst_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rapivab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedIn |
gptkb:Australia
gptkb:Japan gptkb:South_Korea gptkb:United_States |
| gptkbp:mechanismOfAction |
neuraminidase inhibitor
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
diarrhea
hallucination delirium neutropenia |
| gptkbp:usedFor |
influenza
|
| gptkbp:bfsParent |
gptkb:Peramivir
|
| gptkbp:bfsLayer |
7
|